🔗 Share this article Users Discontinuing Weight-Loss Medications Gain Back Pounds Four Times Faster Compared to Those on Conventional Diets Obesity treatment often requires ongoing approaches. Fresh analysis suggests that people who stop using blockbuster GLP-1 drugs like Wegovy and Mounjaro can put back on lost weight far faster than those who end traditional diet and exercise programs. Published data in a prominent health publication points out that while overweight individuals frequently drop about a fifth of their body weight while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month once they quit. "Individuals purchasing such drugs need to be cognizant of the risk of quick weight regain when the treatment concludes," cautioned researcher Dr. Susan Jebb. That rate of regain suggests a return to original mass in about 18 months. Analyzing Therapies The analysis, which reviewed dozens of trials involving thousands of participants, compared the effects of these new drugs with older methods. Researchers emphasize that people who shed pounds through diet and exercise generally see a slower weight regain—perhaps 100 grams monthly—post-intervention. The Reason for the Fast Regain Experts suggest the mechanism of the drugs explains the accelerated weight return. These medications copy a body's own chemical called glucagon-like peptide-1, which moderates appetite. "Long-term administration of the hormone concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert. "Discontinuation of this GLP-1 'fix' leads to appetite is unsuppressed, making excessive eating far more likely." A Chronic Issue? The NHS recommend the injections for individuals with obesity-related health risks, alongside recommended diet and exercise modifications. A number of clinicians contend that, considering the significant potential of relapse, the therapy should be considered life-long. This perspective is echoed by drug manufacturers, who note that the results "highlight the chronic nature of obesity," comparing it to managing diseases like hypertension. User Testimonies Users who have come off the jabs report a sudden resurgence of appetite. "It felt as if something that goes on and I was suddenly ravenous," described an individual. The struggle is exacerbated if individuals have not developed sustainable dietary or behavioural changes during treatment. Significant Interest Survey data indicate that a significant number of people in the UK have tried these injections in the past year, with demand continuing to grow. Use is greater among women compared to males. The 40s and 50s age group shows the greatest level of interest. Many access the medications through private healthcare rather than the NHS. Finally, experts caution that while GLP-1 drugs are effective tools for shedding pounds, they are not a permanent cure and maintained weight loss hinges on ongoing behavioural support.
Obesity treatment often requires ongoing approaches. Fresh analysis suggests that people who stop using blockbuster GLP-1 drugs like Wegovy and Mounjaro can put back on lost weight far faster than those who end traditional diet and exercise programs. Published data in a prominent health publication points out that while overweight individuals frequently drop about a fifth of their body weight while undergoing treatment, the mass returns at an estimated rate of 0.8 kg per month once they quit. "Individuals purchasing such drugs need to be cognizant of the risk of quick weight regain when the treatment concludes," cautioned researcher Dr. Susan Jebb. That rate of regain suggests a return to original mass in about 18 months. Analyzing Therapies The analysis, which reviewed dozens of trials involving thousands of participants, compared the effects of these new drugs with older methods. Researchers emphasize that people who shed pounds through diet and exercise generally see a slower weight regain—perhaps 100 grams monthly—post-intervention. The Reason for the Fast Regain Experts suggest the mechanism of the drugs explains the accelerated weight return. These medications copy a body's own chemical called glucagon-like peptide-1, which moderates appetite. "Long-term administration of the hormone concentrations far above than the body's typical production may cause the body to generate a reduced amount of its own natural GLP-1, and could lessen sensitivity to its effects," explained Dr. Adam Collins, a nutrition expert. "Discontinuation of this GLP-1 'fix' leads to appetite is unsuppressed, making excessive eating far more likely." A Chronic Issue? The NHS recommend the injections for individuals with obesity-related health risks, alongside recommended diet and exercise modifications. A number of clinicians contend that, considering the significant potential of relapse, the therapy should be considered life-long. This perspective is echoed by drug manufacturers, who note that the results "highlight the chronic nature of obesity," comparing it to managing diseases like hypertension. User Testimonies Users who have come off the jabs report a sudden resurgence of appetite. "It felt as if something that goes on and I was suddenly ravenous," described an individual. The struggle is exacerbated if individuals have not developed sustainable dietary or behavioural changes during treatment. Significant Interest Survey data indicate that a significant number of people in the UK have tried these injections in the past year, with demand continuing to grow. Use is greater among women compared to males. The 40s and 50s age group shows the greatest level of interest. Many access the medications through private healthcare rather than the NHS. Finally, experts caution that while GLP-1 drugs are effective tools for shedding pounds, they are not a permanent cure and maintained weight loss hinges on ongoing behavioural support.